SUPPLEMENTARY FINANCIAL DATA (UNAUDITED) (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2022	Sep. 30, 2022	Jun. 30, 2022	Mar. 31, 2022	Dec. 31, 2021	Sep. 30, 2021	Jun. 30, 2021	Mar. 31, 2021	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Total revenue	$ 14,649	$ 12,451	$ 11,050	$ 13,196	$ 14,946	$ 13,194	$ 12,914	$ 14,257	$ 51,346	$ 55,311	$ 71,857
Costs and expenses	32,081	21,595	37,929	51,698	71,113	66,809	77,024	98,149	143,303	313,095	369,484
Loss from operations	(17,432)	(9,144)	(26,879)	(38,502)	(56,167)	(53,615)	(64,110)	(83,892)	(91,957)	(257,784)	(297,627)
Net loss from continuing operations	14,256	10,460	26,570	41,538	57,814	55,910	64,856	86,490	92,824	265,071	294,823
Net income from discontinued operations	3,894	927,091	18,379	15,592	25,780	20,602	12,451	6,811	964,956	65,645	16,806
Net income (loss)	$ (10,362)	$ 916,631	$ (8,191)	$ (25,946)	$ (32,034)	$ (35,308)	$ (52,405)	$ (79,679)	$ 872,132	$ (199,426)	$ (278,017)
Net loss from continuing operations - basic per share	$ (0.21)	$ (0.21)	$ (0.35)	$ (0.55)	$ (0.78)	$ (0.76)	$ (0.99)	$ (1.35)	$ (1.26)	$ (3.82)	$ (4.73)
Net loss from continuing operations - diluted per share	(0.21)	(0.21)	(0.35)	(0.55)	(0.78)	(0.76)	(0.99)	(1.35)	(1.26)	(3.82)	(4.73)
Net income from discontinued operations - basis per share	0.06	12.35	0.24	0.21	0.35	0.28	0.19	0.11	13.11	0.95	0.27
Net income from discontinued operations - diluted per share	0.06	12.35	0.24	0.21	0.35	0.28	0.19	0.11	13.11	0.95	0.27
Net income (loss) - basis	(0.15)	12.14	(0.11)	(0.34)	(0.43)	(0.48)	(0.80)	(1.24)	11.85	(2.87)	(4.46)
Net income (loss) - diluted	$ (0.15)	$ 12.14	$ (0.11)	$ (0.34)	$ (0.43)	$ (0.48)	$ (0.80)	$ (1.24)	$ 11.85	$ (2.87)	$ (4.46)
Percentage of profit share									35.00%
YUPELRI Monotherapy
Total revenue		$ 18,698	$ 17,177	$ 15,283	$ 15,344	$ 13,806	$ 14,621	$ 12,908	$ 19,495
Percentage of Net Sales									35.00%
Mylan
Percentage of profit share									65.00%